Last reviewed · How we verify

Live Francisella Tularensis Vaccine

U.S. Army Medical Research and Development Command · Phase 2 active Biologic

Live Francisella Tularensis Vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 2 development. Also known as: LVS Vaccine.

At a glance

Generic nameLive Francisella Tularensis Vaccine
Also known asLVS Vaccine
SponsorU.S. Army Medical Research and Development Command
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Live Francisella Tularensis Vaccine

What is Live Francisella Tularensis Vaccine?

Live Francisella Tularensis Vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command.

Who makes Live Francisella Tularensis Vaccine?

Live Francisella Tularensis Vaccine is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).

Is Live Francisella Tularensis Vaccine also known as anything else?

Live Francisella Tularensis Vaccine is also known as LVS Vaccine.

What development phase is Live Francisella Tularensis Vaccine in?

Live Francisella Tularensis Vaccine is in Phase 2.

Related